Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate Catherine M. E. BarnettNatasa BroitGlen M. Boyle PRECLINICAL STUDIES Open access 18 April 2018 Pages: 1 - 8
Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides Tammy Price-TroskaZhi-Zhang YangStephen M. Ansell PRECLINICAL STUDIES 26 April 2018 Pages: 9 - 16
Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists A. Molinos-QuintanaP. Trujillo-HachaMiguel Muñoz PRECLINICAL STUDIES 02 May 2018 Pages: 17 - 26
Copper-tolfenamic acid: evaluation of stability and anti-cancer activity Myrna HurtadoUmesh T. SankpalRiyaz Basha PRECLINICAL STUDIES 15 May 2018 Pages: 27 - 34
Discovering simple phenylboronic acid and benzoxaborole derivatives for experimental oncology – phase cycle-specific inducers of apoptosis in A2780 ovarian cancer cells Mateusz PsurskiAgnieszka Łupicka-SłowikAndrzej Sporzyński PRECLINICAL STUDIES Open access 19 May 2018 Pages: 35 - 46
Immuno-therapeutic potential of Schistosoma mansoni and Trichinella spiralis antigens in a murine model of colon cancer Maha M. EissaCherine A. IsmailMona A. Hadi PRECLINICAL STUDIES 28 May 2018 Pages: 47 - 56
Preclinical study of the antitumor effect of sphingosine-1-phosphate receptor 1 antibody (S1PR1-antibody) against human breast cancer cells Shujun XiaoJian Yang PRECLINICAL STUDIES 02 June 2018 Pages: 57 - 64
The poly (ADP-ribose) polymerase inhibitor rucaparib suppresses proliferation and serves as an effective radiosensitizer in cervical cancer Mei TangQiuli LiuHaifeng Qiu PRECLINICAL STUDIES 06 June 2018 Pages: 65 - 75
Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules Kamalesh SankhalaChris H. TakimotoScott Kopetz PHASE I STUDIES 18 April 2018 Pages: 76 - 86
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors A Craig LockhartTodd M. BauerAfshin Dowlati PHASE I STUDIES Open access 21 May 2018 Pages: 87 - 97
A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study Manuel Ruiz-BorregoBegoña JimenezMiguel Martín PHASE I STUDIES 09 June 2018 Pages: 98 - 108
Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer Masafumi IkedaIzumi OhnoChigusa Morizane PHASE I STUDIES 11 July 2018 Pages: 109 - 117
A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma Masafumi IkedaManabu MorimotoDaisuke Sakai PHASE I STUDIES Open access 11 July 2018 Pages: 118 - 126
Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial Christian DittrichRobert KönigsbergPhilipp Buchner PHASE I STUDIES 12 July 2018 Pages: 127 - 138
Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects Zhi-Yi ZhangJing WangXiaodong Wang PHASE I STUDIES 21 July 2018 Pages: 139 - 146
First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors Kathleen N. MooreJohanna C. BendellGiorgio Senaldi PHASE I STUDIES 28 July 2018 Pages: 147 - 158
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma Kimmie NgAndrew HendifarCharles S. Fuchs SHORT REPORT Open access 30 July 2018 Pages: 159 - 165
Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991–2015 Kota ItahashiToshio ShimizuNoboru Yamamoto REVIEW 07 August 2018 Pages: 166 - 174
Advanced development of ErbB family-targeted therapies in osteosarcoma treatment Wei WangHua-fu ZhaoHao Gong REVIEW 24 October 2018 Pages: 175 - 183
Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein Takahisa KawamuraHaruyasu MurakamiToshiaki Takahashi SHORT REPORT 03 July 2018 Pages: 184 - 187
Antitumor evaluation of novel phenothiazine derivatives that inhibit migration and tubulin polymerization against gastric cancer MGC-803 cells Nan LiuZhe JinJianjun Jin SHORT REPORT 22 October 2018 Pages: 188 - 198